Integra LifeSciences Holdings Co. (NASDAQ:IART) Given Average Rating of “Reduce” by Analysts

Shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) have received a consensus recommendation of “Reduce” from the seven analysts that are currently covering the company, MarketBeat.com reports. Three analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $47.29.

Several research firms recently commented on IART. StockNews.com started coverage on Integra LifeSciences in a research note on Thursday, August 17th. They set a “hold” rating for the company. Truist Financial boosted their target price on shares of Integra LifeSciences from $44.00 to $48.00 in a research report on Wednesday, July 19th. JMP Securities reduced their price target on shares of Integra LifeSciences from $65.00 to $60.00 and set an “outperform” rating for the company in a report on Friday, July 28th. Piper Sandler dropped their price objective on shares of Integra LifeSciences from $55.00 to $44.00 in a report on Monday, June 26th. Finally, TheStreet lowered Integra LifeSciences from a “b-” rating to a “c+” rating in a research report on Monday, May 22nd.

Integra LifeSciences Price Performance

NASDAQ:IART opened at $39.11 on Thursday. The company has a current ratio of 2.78, a quick ratio of 1.85 and a debt-to-equity ratio of 0.79. The firm has a fifty day simple moving average of $42.94 and a 200 day simple moving average of $47.25. Integra LifeSciences has a 1-year low of $37.36 and a 1-year high of $60.69. The stock has a market capitalization of $3.18 billion, a PE ratio of 24.91, a P/E/G ratio of 1.56 and a beta of 1.20.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.57 by $0.14. Integra LifeSciences had a net margin of 8.49% and a return on equity of 15.60%. The company had revenue of $381.30 million for the quarter, compared to analyst estimates of $388.79 million. During the same period in the previous year, the business earned $0.82 EPS. Integra LifeSciences’s revenue for the quarter was down 4.1% compared to the same quarter last year. On average, research analysts expect that Integra LifeSciences will post 3.14 EPS for the current fiscal year.

Institutional Trading of Integra LifeSciences

Institutional investors have recently bought and sold shares of the stock. Itau Unibanco Holding S.A. raised its position in shares of Integra LifeSciences by 469.5% in the second quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock valued at $31,000 after buying an additional 615 shares during the last quarter. CWM LLC raised its stake in shares of Integra LifeSciences by 107.0% in the second quarter. CWM LLC now owns 828 shares of the life sciences company’s stock valued at $34,000 after acquiring an additional 428 shares in the last quarter. Global Retirement Partners LLC grew its stake in Integra LifeSciences by 3,103.7% during the 1st quarter. Global Retirement Partners LLC now owns 865 shares of the life sciences company’s stock worth $44,000 after purchasing an additional 838 shares in the last quarter. Coppell Advisory Solutions LLC acquired a new stake in Integra LifeSciences in the 2nd quarter valued at about $84,000. Finally, Covestor Ltd raised its holdings in Integra LifeSciences by 63.0% in the first quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock valued at $100,000 after acquiring an additional 602 shares in the last quarter. 84.13% of the stock is currently owned by institutional investors and hedge funds.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corp. engages in the provision of regenerative tissue technologies and neurological solutions dedicated to limiting uncertainty for clinicians. It operates under the Codman Specialty Surgical (CSS) and Tissue Technologies (TT) segments. The CSS segment includes technologies and instrumentation used for neurosurgery, neurocritical care, and otolaryngology.